Literature DB >> 24062395

Endothelial damage in long-term survivors of childhood cancer.

Cornelia A J Brouwer1, Aleida Postma, H Louise H Hooimeijer, Andries J Smit, Judith M Vonk, Arie M van Roon, Maarten P van den Berg, Wil V Dolsma, Joop D Lefrandt, Margreet T E Bink-Boelkens, Nynke Zwart, Elisabeth G E de Vries, Wim J E Tissing, Jourik A Gietema.   

Abstract

PURPOSE: To evaluate the presence of vascular damage in long-term childhood cancer survivors (CCS) and sibling controls, and to evaluate the association between vascular damage parameters and cancer treatment and influence of cardiovascular risk factors. PATIENTS AND METHODS: Vascular assessment was performed in 277 adult CCSs (median age at diagnosis, 9 years; range, 0 to 20 years; median current age, 28 years; range, 18 to 48 years) treated with potentially cardiovascular toxic anticancer treatment (ie, anthracyclines, platinum, and/or radiotherapy [RT]). Measurements included carotid- and femoral-wall intima-media thickness (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial and inflammatory marker proteins (including tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-I]), and cardiovascular risk factors. CCS assessments were compared with those of 130 sibling controls (median age, 26 years; range, 18 to 51 years).
RESULTS: At a median of 18 years (range, 5 to 31 years) after treatment, carotid and femoral IMTs in CCSs were not different from those of controls. However, CCSs who received RT as part of their treatment regimen had increased carotid and femoral IMTs and higher t-PA and PAI-I levels, indicating vascular damage and persistent endothelial activation. Patients treated with RT to the neck or chest also had greater femoral IMT. Greater IMT was associated with presence of cardiovascular risk factors (eg, hypertension and overweight).
CONCLUSION: After potentially cardiovascular toxic anticancer treatment, CCSs who received RT showed signs of endothelial damage and an unfavorable cardiovascular risk profile compared with controls. CCSs treated with localized RT had increased IMT outside the primary irradiation field. These abnormalities are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24062395     DOI: 10.1200/JCO.2012.46.6086

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.

Authors:  Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

2.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Authors:  Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

3.  Tissue-engineered blood vessels as promising tools for testing drug toxicity.

Authors:  George A Truskey; Cristina E Fernandez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-31       Impact factor: 4.481

4.  Physical activity and cardiovascular risk factors in childhood cancer survivors.

Authors:  Megan E Slater; Julie A Ross; Aaron S Kelly; Donald R Dengel; James S Hodges; Alan R Sinaiko; Antoinette Moran; Jill Lee; Joanna L Perkins; Lisa S Chow; K Scott Baker; Julia Steinberger
Journal:  Pediatr Blood Cancer       Date:  2014-10-18       Impact factor: 3.167

5.  Cognitive impairment persists at least 1 year after juvenile rats are treated with methotrexate.

Authors:  Jing Wen; Chadni Patel; Frank Diglio; Kayla Baker; Gregory Marshall; Shengguo Li; Peter D Cole
Journal:  Neuropharmacology       Date:  2022-01-02       Impact factor: 5.250

6.  Feasibility and preliminary efficacy of the effects of flavanoid-rich purple grape juice on the vascular health of childhood cancer survivors: a randomized, controlled crossover trial.

Authors:  Cindy K Blair; Aaron S Kelly; Julia Steinberger; Lynn E Eberly; Char Napurski; Kim Robien; Joseph P Neglia; Daniel A Mulrooney; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167

Review 7.  The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.

Authors:  Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-12       Impact factor: 4.733

8.  Communicating health information and improving coordination with primary care (CHIIP): Rationale and design of a randomized cardiovascular health promotion trial for adult survivors of childhood cancer.

Authors:  Eric J Chow; Laura-Mae Baldwin; Anna M Hagen; Melissa M Hudson; Todd M Gibson; Komal Kochar; Aaron McDonald; Paul C Nathan; Karen L Syrjala; Sarah L Taylor; Emily S Tonorezos; Yutaka Yasui; Gregory T Armstrong; Kevin C Oeffinger
Journal:  Contemp Clin Trials       Date:  2019-12-17       Impact factor: 2.226

Review 9.  Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer.

Authors:  Amy M Berkman; Susan G Lakoski
Journal:  J Am Heart Assoc       Date:  2015-04-02       Impact factor: 5.501

10.  Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.

Authors:  Renske Altena; Rudolf S N Fehrmann; Hink Boer; Elisabeth G E de Vries; Coby Meijer; Jourik A Gietema
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.